|
Sign In to gain access to subscriptions and/or personal tools.
|
Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis — are we there yet?
S. Amor
Neuroimmunology Unit Neuroscience Centre Institute of Cell and Molecular Science Barts and The London Queen Mary's School of Medicine and Dentistry 4 Newark Street London E1 2AT, Department of Pathology VU University Medical Centre Amsterdam The Netherlands
G. Giovannoni
Neuroimmunology Unit Neuroscience Centre Institute of Cell and Molecular Science Barts and The London Queen Mary's School of Medicine and Dentistry 4 Newark Street London E1 2AT, g.giovannoni{at}qmul.ac.uk
References
- Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707—17.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Smith PA, Heijmans N., Ouwerling B. et al. Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice. Eur J Immunol 2005; 35(4): 1311—9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Morris-Downes MM, Smith PA, Rundle JL et al. Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J Neuroimmunol 2002; 125(1—2): 114—24.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Burrer R., Buchmeier MJ, Wolfe T. et al. Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. Am J Pathol 2007; 170(2): 557—66.[Abstract/Free Full Text]
- Wallberg M., Bergquist J., Achour A., Breij E., Harris RA Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur J Immunol 2007; 37(7): 1986—95.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Xiao BG, Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991; 31(2): 91—6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Berger T., Rubner P., Schautzer F. et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349(2): 139—45.[Abstract/Free Full Text]
- Tomassini V., De Giglio L., Reindl M. et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007;
- Lim ET, Berger T., Reindl M. et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11(4): 492—4.[Abstract/Free Full Text]
- Rauer S., Euler B., Reindl M., Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006; 77(6): 739—42.[Abstract/Free Full Text]
- Pelayo R., Tintore M., Montalban X. et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007; 356(4): 426—8.[Free Full Text]
- Pittock SJ, Reindl M., Achenbach S. et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007; 13(1): 7—16.[Abstract/Free Full Text]
- Kuhle J., Lindberg RL, Regeniter A. et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007; 254(2): 160—8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kuhle J., Pohl C., Mehling M. et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356(4): 371—8.[Abstract/Free Full Text]
- Lampasona V., Franciotta D., Furlan R. et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004; 62(11): 2092—4.[Abstract/Free Full Text]
- Lalive PH, Menge T., Delarasse C. et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103(7): 2280—5.[Abstract/Free Full Text]
- Zhou D., Srivastava R., Nessler S. et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103(50): 19057—62.[Abstract/Free Full Text]
- O'Connor KC, McLaughlin KA, De Jager PL et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13(2): 211—7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lucchinetti CF, Bruck W., Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56(2): 308.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005; 102(39): 13992—7.[Abstract/Free Full Text]
Multiple Sclerosis, Vol. 13, No. 9,
1083-1085 (2007)
DOI: 10.1177/1352458507084431
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
